Fluorene

Fluorene

SCHEMBL1883201

C=C(C)C(=O)OC(C)(Oc1ccccc1)Oc1ccccc1.c1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.38
MAOA P21397 2/20 0.38
CYP1A2 P05177 2/20 0.38
ADRA2A P08913 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
SLC6A4 P31645 1/20 0.38
HTR2B P41595 1/20 0.38
ELANE P08246 1/20 0.37
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 1/20 0.34
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorene SCHEMBL2126074 0.97 SRD5A2 (0.37) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL8023534 0.83 KMT2A (0.40) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL4456503 0.82 SRD5A2 (0.38) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL2126077 0.81 SRD5A2 (0.40) SRD5A2MAOACYP1A2ADRA2ASLC6A2
SCHEMBL27856144 0.77 ELANE (0.39) CYP1A2ELANEALDH1A1MAPTKDM4E
SCHEMBL9780106 0.76 PPARG (0.41) CYP1A2ELANERAB9ANPC1ALDH1A1
Fluorene SCHEMBL608981 0.75 ALDH1A1 (0.52) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL1151459 0.75 SRD5A2 (0.53) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL2127827 0.75 SRD5A2 (0.53) SRD5A2MAOACYP1A2ADRA2ASLC6A2
Fluorene SCHEMBL29848606 0.75 SRD5A2 (0.53) SRD5A2MAOACYP1A2ADRA2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024085208-A1 COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAM RECORDING MEDIUM, OPTICAL MATERIAL, AND OPTICAL COMPONENT 三菱ケミカル株式会社 2024-04-25 WO disclosed
WO-2024063135-A1 COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAM RECORDING MEDIUM, OPTICAL MATERIAL, AND OPTICAL COMPONENT 三菱ケミカル株式会社 2024-03-28 WO disclosed
WO-2024043165-A1 CURABLE COMPOSITION AND COMPOSITE MATERIAL 日東電工株式会社 2024-02-29 WO disclosed
EP-4317155-A1 COMPOUND, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAPHIC RECORDING MEDIUM, OPTICAL MATERIAL, AND OPTICAL COMPONENT Mitsubishi Chemical Corporation (JP) 2024-02-07 EP disclosed
US-20240018137-A1 COMPOUND, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAPHIC RECORDING MEDIUM, OPTICAL MATERIAL, AND OPTICAL COMPONENT MITSUBISHI CHEMICAL CORPORATION (JP) 2024-01-18 US disclosed
WO-2024005140-A1 COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAPHIC RECORDING MEDIUM, OPTICAL MATERIAL AND OPTICAL COMPONENT 三菱ケミカル株式会社 2024-01-04 WO disclosed
US-10981352-B2 Method for producing optical member, and optical member SHARP KABUSHIKI KAISHA (JP) 2021-04-20 US disclosed
US-20190118504-A1 METHOD FOR PRODUCING OPTICAL MEMBER, AND OPTICAL MEMBER SHARP KABUSHIKI KAISHA (JP) 2019-04-25 US disclosed
US-9685597-B2 Curable composition for sealing optical semiconductor DAICEL CORPORATION (JP) 2017-06-20 US disclosed
US-20160126431-A1 CURABLE COMPOSITION FOR SEALING OPTICAL SEMICONDUCTOR DAICEL CORPORATION (JP) 2016-05-05 US disclosed
US-8507632-B2 A polyesterurethane copolymer containing a polycaprolactone-modified alkyl(meth)acrylate; self-repairing coatings or paints; optical films NATOCO CO., LTD. (JP) 2013-08-13 US disclosed
EP-2077471-B1 VOLUME HOLOGRAM OPTICAL RECORDING MEDIUM, COMPOSITION FOR VOLUME HOLOGRAM RECORDING LAYER FORMATION, AND VOLUME HOLOGRAM RECORDING MATERIAL MITSUBISHI CHEM CORP (JP) 2012-07-25 EP disclosed
US-7939608-B2 A polyesterurethane copolymer containing a polycaprolactone-modified alkyl(meth)acrylate; self-repairing coatings or paints; optical films NATOCO CO., LTD. (JP) 2011-05-10 US disclosed
US-20100067073-A1 VOLUME HOLOGRAM OPTICAL RECORDING MEDIUM, COMPOSITION FOR VOLUME HOLOGRAM RECORDING LAYER FORMATION, AND VOLUME HOLOGRAM RECORDING MATERIAL MITSUBISHI CHEMICAL CORPORATION (JP) 2010-03-18 US disclosed
EP-2077471-A1 VOLUME HOLOGRAM OPTICAL RECORDING MEDIUM, COMPOSITION FOR VOLUME HOLOGRAM RECORDING LAYER FORMATION, AND VOLUME HOLOGRAM RECORDING MATERIAL Mitsubishi Chemical Corporation (JP) 2009-07-08 EP disclosed
US-20080125550-A1 COMPOSITION CURABLE WITH ACTINIC ENERGY RAY AND USE THEREOF NATOCO CO., LTD. (JP) 2008-05-29 US disclosed
US-20070049654-A1 Composition Curable With Actinic Energy Ray and Use Thereof NATOCO CO., LTD. (JP) 2007-03-01 US disclosed
US-20070049653-A1 Composition Curable With Actinic Energy Ray and Use Thereof NATOCO CO., LTD. (JP) 2007-03-01 US disclosed
US-20070004817-A1 Composition Curable With Actinic Energy Ray and Use Thereof NATOCO CO., LTD. (JP) 2007-01-04 US disclosed
US-20050148739-A1 Composition curable with actinic energy ray and use thereof NATOCO CO., LTD. (JP) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018137-A1 COMPOUND, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, POLYMER, HOLOGRAPHIC RECORDING MEDIUM, OPTICAL MATERIAL, AND OPTICAL COMPONENT F12, SEM1, NOX1 SRD5A2 997/4885MAOA 1344/4885CYP1A2 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.